AAN 2024 Poster - INTERCEPT-AD, a Phase 1 Study of Sabirnetug (ACU193): Safety, Target Engagement, and Biomarker Changes May 1, 2024 AAN 2024 Oral Presentation May 1, 2024 Corporate Presentation March 19, 2024 ADPD 2024 CSF Biomarker Presentation March 8, 2024 J.P. Morgan Healthcare Conference Presentation January 8, 2024 Q3 2023 Financial Results & Business Update November 13, 2023 CTAD Symposium Presentation 2023 October 26, 2023 Q2 2023 Financial Results & Business Update August 8, 2023 Investor Presentation Discussing Topline Results of Phase 1 INTERCEPT-AD Trial’ July 17, 2023 INTERCEPT-AD Topline Results Presentation at AAIC July 17, 2023 Pagination Current page 1 Page 2 Next page next › Last page last »
AAN 2024 Poster - INTERCEPT-AD, a Phase 1 Study of Sabirnetug (ACU193): Safety, Target Engagement, and Biomarker Changes May 1, 2024